Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers

被引:121
作者
Witkiewicz, Agnieszka K. [1 ,2 ]
Dasgupta, Abhijit [2 ,3 ]
Sammons, Sara [1 ]
Er, Ozlem [2 ,4 ,5 ]
Potoczek, Magdalena B. [1 ,2 ,4 ]
Guiles, Fran [2 ,6 ]
Sotgia, Federica [2 ,5 ]
Brody, Jonathan R. [7 ]
Mitchell, Edith P. [2 ,6 ]
Lisanti, Michael P. [2 ,4 ,5 ,6 ,8 ,9 ]
机构
[1] Thomas Jefferson Univ, Dept Pathol, Jefferson Ctr Pancreat Biliary & Related Canc, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Stem Cell Biol & Regenerat Med Ctr, Philadelphia, PA 19107 USA
[3] Thomas Jefferson Univ, Div Biostat, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA
[4] Thomas Jefferson Univ, Dept Stem Cell Biol & Regenerat Med, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[5] Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[6] Thomas Jefferson Univ, Dept Med Oncol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[7] Thomas Jefferson Univ, Dept Surg, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[8] Univ Manchester, Manchester Breast Ctr, Manchester M13 9PL, Lancs, England
[9] Univ Manchester, Breakthrough Breast Canc Res Unit, Sch Canc Enabling Sci & Technol, Paterson Inst Canc Res,Manchester Acad Hlth Sci C, Manchester M13 9PL, Lancs, England
关键词
caveolin-1; mammary tumor stroma; stromal biomarkers; cancer survival; cancer-associated fibroblasts; PHENOTYPE; FIBROBLASTS; SUBTYPES; THERAPY;
D O I
10.4161/cbt.10.2.11983
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Here, we investigated the possible predictive value of stromal caveolin-1 (Cav-1) as a candidate biomarker for clinical outcome in triple negative (TN) breast cancer patients. A cohort of 85 TN breast cancer patients was available, with the necessary annotation and nearly 12 years of follow-up data. Our primary outcome of interest in this study was overall survival. Interestingly, TN patients with high-levels of stromal Cav-1 had a good clinical outcome, with >50% of the patients remaining alive during the follow-up period. In contrast, the median survival for TN patients with moderate stromal Cav-1 staining was 33.5 months. Similarly, the median survival for TN patients with absent stromal Cav-1 staining was 25.7 months. A comparison of 5-year survival rates yields a similar pattern. TN patients with high stromal Cav-1 had a good 5-year survival rate, with 75.5% of the patients remaining alive. In contrast, TN patients with moderate or absent stromal Cav-1 levels had progressively worse 5-year survival rates, with 40% and 9.4% of the patients remaining alive. In contrast, in a parallel analysis, the levels of tumor epithelial Cav-1 had no prognostic significance. As such, the prognostic value of Cav-1 immunostaining in TN breast cancer patients is compartment-specific, and selective for an absence of Cav-1 staining in the stromal fibroblast compartment. A recursive-partitioning algorithm was used to assess which factors are most predictive of overall survival in TN breast cancer patients. In this analysis, we included tumor size, histologic grade, whether the patient received surgery, radiotherapy or chemotherapy, CK5/6, EGFR, p53 and Ki67 status, as well as the stromal Cav-1 score. This analysis indicated that stromal loss of Cav-1 expression was the most important prognostic factor for overall survival in TN breast cancer. Virtually identical results were obtained with CK5/6 (+) and/or EGFR (+) TN breast cancer cases, demonstrating that a loss of stromal Cav-1 is also a strong prognostic factor for basal-like breast cancers. Our current findings may have important implications for the close monitoring and treatment stratification of TN and basal-like breast cancer patients.
引用
收藏
页码:135 / 143
页数:9
相关论文
共 23 条
[1]   Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].
Bauer, Katrina R. ;
Brown, Monica ;
Cress, Rosemary D. ;
Parise, Carol A. ;
Caggiano, Vincent .
CANCER, 2007, 109 (09) :1721-1728
[2]  
BONUCCELLI G, 2010, CELL CYCLE IN PRESS, V9
[3]   Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype [J].
Cheang, Maggie C. U. ;
Voduc, David ;
Bajdik, Chris ;
Leung, Samuel ;
McKinney, Steven ;
Chia, Stephen K. ;
Perou, Charles M. ;
Nielsen, Torsten O. .
CLINICAL CANCER RESEARCH, 2008, 14 (05) :1368-1376
[4]   Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes [J].
Desmedt, Christine ;
Haibe-Kains, Benjamin ;
Wirapati, Pratyaksha ;
Buyse, Marc ;
Larsimont, Denis ;
Bontempi, Gianluca ;
Delorenzi, Mauro ;
Piccart, Martine ;
Sotiriou, Christos .
CLINICAL CANCER RESEARCH, 2008, 14 (16) :5158-5165
[5]   Expression of luminal and basal cytokeratins in human breast carcinoma [J].
El-Rehim, DMA ;
Pinder, SE ;
Paish, CE ;
Bell, J ;
Blamey, R ;
Robertson, JFR ;
Nicholson, RI ;
Ellis, IO .
JOURNAL OF PATHOLOGY, 2004, 203 (02) :661-671
[6]   Caveolin 1 and caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype [J].
Elsheikh, S. E. ;
Green, A. R. ;
Rakha, E. A. ;
Samaka, R. M. ;
Ammar, A. A. ;
Powe, D. ;
Reis-Filho, J. S. ;
Ellis, I. O. .
BRITISH JOURNAL OF CANCER, 2008, 99 (02) :327-334
[7]  
Elston C W, 2002, Histopathology, V41, P154
[8]  
Hamperl H, 1970, Curr Top Pathol, V53, P161
[9]   Unbiased recursive partitioning: A conditional inference framework [J].
Hothorn, Torsten ;
Hornik, Kurt ;
Zeileis, Achim .
JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS, 2006, 15 (03) :651-674
[10]   Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers [J].
Jumppanen, Mervi ;
Gruvberger-Saal, Sofia ;
Kauraniemi, Paivikki ;
Tanner, Minna ;
Bendahl, Par-Ola ;
Lundin, Mikael ;
Krogh, Morten ;
Kataja, Pasi ;
Borg, Ake ;
Ferno, Marten ;
Isola, Jorma .
BREAST CANCER RESEARCH, 2007, 9 (01)